



Living Cell Technologies Limited

**COMPANY ANNOUNCEMENT:
Results of Annual General Meeting held on 19 November 2009**

(ASX: LCT; OTCQX: LVCLY)

ASX Announcement – 19 November 2009

The following voting results are in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Ltd held today is provided in accordance with Listing Rule 3.13.2 and section 251AA (2) of the Corporations Act.

The Chairman announced that he would vote all undirected proxies in favour of all resolutions.

The total number of proxy votes exercisable by all proxies validly appointed was 56,242,308.

Resolution 1 Remuneration Report (non binding):

“That the Remuneration Report required by section 300A of the Corporations Act, as contained in the Director’s Report of the Company, for the year ended 30 June 2008 be adopted.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|------------|---------|------------|
| 43,760,423 | 12,050,572 | 84,444 | 346,869 |

Resolution 2 Election of Mr Robert Finder

“That Robert Finder, who was appointed a Director during the year, and who retires in accordance with Clause 9.2 of the Company’s Constitution and, being eligible, offers himself for election, be elected as a Director of the Company. Details of which are set out in the explanatory notes to resolution 2 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|---------|---------|------------|
| 55,893,439 | 1,000 | 1,000 | 346,869 |



Living Cell Technologies Limited
ABN 14 104 028 042
2

Resolution 3 Election of Mr David McAuliffe

“That David McAuliffe, who was appointed a Director during the year, and who retires in accordance with Clause 9.2 of the Company’s Constitution and, being eligible, offers himself for election, be elected as a Director of the Company. Details of which are set out in the explanatory notes to resolution 3 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|---------|---------|------------|
| 55,894,439 | 1,000 | - | 346,869 |

Resolution 4 Re-election of Professor Robert Elliott

“That Professor Robert Elliott retires by rotation in accordance with Clause 6.1 of the Company’s Constitution and being eligible, offers himself for re-election, details of which are set out in the explanatory notes to resolution 4 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|---------|---------|------------|
| 55,885,989 | 9,450 | - | 346,869 |

Resolution 5 Re-election of Mr Laurie Hunter

“That Mr Laurie Hunter retires by rotation in accordance with Clause 6.1 of the Company’s Constitution and being eligible, offers himself for re-election, details of which are set out in the explanatory notes to resolution 5 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|---------|---------|------------|
| 55,252,499 | 636,644 | 6,296 | 346,869 |



Living Cell Technologies Limited
ABN 14 104 028 042
3

Resolution 6 Approval of issue of options to Robert Finder or his nominee in accordance with Listing Rule 10.11

“That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 150,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.25 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.35 per share to Robert Finder or his nominee, details of which are set out in the explanatory notes to resolution 6 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|------------|---------|------------|
| 43,713,098 | 12,166,045 | 6,296 | 346,869 |

Resolution 7 Approval of issue of options to David McAuliffe or his nominee in accordance with Listing Rule 10.11

“That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 150,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.25 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.35 per share to David McAuliffe or his nominee, details of which are set out in the explanatory notes to resolution 7 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|------------|---------|------------|
| 43,718,394 | 12,166,045 | 1,000 | 346,869 |

Resolution 8 Approval of issue of options to David Brookes or his nominee in accordance with Listing Rule 10.11

“That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.25 per share and 250,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.35 per share to David Brookes or his nominee, details of which are set out in the explanatory notes to resolution 8 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|------------|---------|------------|
| 43,243,394 | 12,166,045 | 486,000 | 346,869 |



Living Cell Technologies Limited
ABN 14 104 028 042
4

Resolution 9 Approval of Directors Deed of Access, Insurance and Indemnity

“That for the purposes of section 195(4) of the *Corporations Act 2001* and all other purposes:

1. approval is given to the Company to enter into a Director’s Deed of Access, Insurance and Indemnity between the Company and each of the current Directors of the Company, in substantially the same form as that which is submitted to the 2009 Annual General Meeting, and signed by the Chairman for identification, and to the Company providing benefits in accordance with the Deeds to each of the current Directors; and
2. any Director and the Secretary of the Company be authorised to sign, seal and deliver on behalf of the Company, each such Director’s Deed of Access, Insurance and Indemnity. Details of which are set out in the explanatory notes to resolution 9 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

| FOR | AGAINST | ABSTAIN | UNDIRECTED |
|------------|---------|---------|------------|
| 55,268,143 | 137,000 | 490,296 | 346,869 |

By order of the board

A handwritten signature in black ink, appearing to read 'Nick Geddes', with a horizontal line underneath.

Nick Geddes
Company Secretary

-Ends-

For further information: www.lctglobal.com

Dr. Paul Tan
Chief Executive Officer
Mob: 021 608 784 (NZ)
Tel: +64 9 276 2690
ptan@lctglobal.com

Prof. Bob Elliott
Medical Director
Mob: +64 27 292 4177
Tel: +64 9 276 2690
belliot@lctglobal.com

Mr John Cowan
Finance & Administration Manager
Tel: +64 9 276 2690
jcowan@lctglobal.com

Paul Dekkers
Investor and Media Relations
Tel: +612 9237 2800
pdekkers@bcg.com.au



About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.